Thermo Fisher Scientific and My Green Lab Collaborate to Expand Use of ACT Label in Driving Environmentally Sustainable Lab Practices

- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of its collaboration with My Green Lab a non-profit organization committed to improving the environmental sustainability of scientific research. The company has set a goal to obtain Accountability, Consistency and Transparency (ACT) labelling for its entire cold temperature storage portfolio by the end of 2021. Over time, Thermo Fisher expects to ACT label more than 1,200 additional SKUs, enabling research, pharmaceutical and clinical laboratories to achieve their sustainability objectives by providing a broader range of purchasing options.

Thermo Fisher Scientific logo (PRNewsfoto/Thermo Fisher Scientific)

"Our customers are committed to adopting more sustainable laboratory practices, and My Green Lab enables them to take proactive steps to meet their objectives," said Paul Parker , senior vice president of strategy and corporate development for Thermo Fisher Scientific. "We are proud of our efforts to support environmentally friendly laboratory management, in part, with a portfolio of laboratory equipment and consumables that has earned top scores across a range of sustainability metrics. The ACT label serves as an objective tool for making impactful and responsible purchasing decisions."

Thermo Fisher's freezers are among the first to be ENERGY STAR® certified by the U.S. Environmental Protection Agency (EPA) . The systems are powered by Thermo Fisher's unique V-Drive technology, designed to detect and adapt to changing usage patterns, and adjust compressor speed, offering significant energy savings without compromising performance. The freezers use environmentally friendly hydrocarbon refrigerants that meet the requirements of the US EPA's Significant New Alternatives Policy (SNAP) and the European Union's F-Gas Regulation, which focus on the elimination of ozone-depleting refrigerants.

"The ACT Label program provides the unique opportunity for laboratories to reduce their environmental impact by allowing purchasers to compare products and make informed buying decisions based on sustainable manufacturing, use and disposal practices," said James Connelly , chief executive officer, My Green Lab . "Thermo Fisher Scientific has been a key driver in this effort, helping establish a culture of sustainability through eco-friendly cold storage solutions. We rely on this long-standing collaboration to further expand the ACT Label program to ensure global scientific research reflects the highest standards of environmental responsibility."

The Thermo Scientific TSX Series ULT freezers and the Thermo Scientific Standard Performance (STP) ULT freezers were the company's first cold storage solutions to be recognized with the ACT label. Today, more than 200 models are similarly labeled. These systems provide a 70 percent reduction in energy consumption compared with conventional options. The instruments are manufactured in an award-winning, zero waste-to-landfill facility. Thermo Fisher's collaboration with My Green Lab began in 2017 when it participated in the ACT Label pilot program for laboratory consumables. The company now offers about 100 products within its plastic consumables and reagents businesses that are ACT labelled.

This video provides more about Thermo Fisher's work with My Green Lab . For more information about Thermo Fisher's complete offering of environmentally friendly freezers, please visit www.thermofisher.com/cold .

About Thermo Fisher Scientific  
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone:  781-622-1356
E-mail: rafael.tejada@thermofisher.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-and-my-green-lab-collaborate-to-expand-use-of-act-label-in-driving-environmentally-sustainable-lab-practices-301331879.html

SOURCE Thermo Fisher Scientific

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×